Evidence for Rescheduling Hydrocodone Combination Products?

Published Online: Thursday, January 9, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that there is no evidence to support categorizing hydrocodone combination products as Schedule II drugs rather than Schedule III drugs.

This is the part of a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. To see the first video in the series, in which Dr. McPherson discusses the dramatic increase in the use of opioids in the United States, click here. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)

These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Up to 15% of patients who receive a statin experience muscle pain, for which clinicians have only a few options: prescribing a different statin, reducing the dose of the current statin, or stopping statin therapy entirely.
A drug therapy for epilepsy and shingles pain is being voluntarily recalled by its manufacturer due to complaints of empty capsules.
A former pharmacy technician thought the prescription pill records she was finagling were better shred than read.
Latest Issues
$auto_registration$